Aim To identify ethnic differences in hypoglycaemic risk among people with Type 2 diabetes prescribed insulins and/or sulfonylureas in community settings.
Introduction
Intensive glycaemic control using insulins and sulfonylureas substantially increases the risk of hypoglycaemia [1] [2] [3] . Most hypoglycaemia is asymptomatic and self-managed, but when hypoglycaemia is more severe it is characterized by autonomic and neuroglycopenic symptoms, which may be fatal if not treated promptly, and is associated with a greater risk of hospital admission.
A recent study of hypoglycaemia in hospital settings in the UK found that black Caribbean people were at higher risk of hospitalization for hypoglycaemia than white Europeans, but Bangladeshi, Pakistani and Indian people were at lower risk [4] . There is also limited evidence, mainly from hospital settings in the USA, that ethnic minority groups (AfricanAmerican, Hispanic and Asian people) with Type 2 diabetes are at increased risk of hypoglycaemia compared with nonHispanic white people [5] [6] [7] [8] .
The effects of therapy may vary according to an individual's ethnicity. For example, African American people in a large health system had better glycaemic responses to metformin than their European American counterparts [9] . Furthermore, analysis of 11 multinational trials found that people of African and Asian descent using insulins had significantly higher risks of hypoglycaemia than white Europeans [10] . Additionally, South Asian people appear less compliant with insulin regimes or prefer the use of simpler basal-only insulins [11] [12] [13] .
The aim of the present study was to establish whether the risk of clinically recorded hypoglycaemia in primary care records differed between and within the major ethnic groups in east London after adjusting for age, sex, socioeconomic deprivation and clustering within Clinical Commissioning Groups (CCGs) in those with Type 2 diabetes prescribed insulins and/or sulfonylureas. Given possible ethnic variations in adherence and responses to antidiabetes agents, a secondary aim was to identify any interaction between ethnicity and type of antidiabetes medication, i.e. insulins or sulfonylureas, on the risk of hypoglycaemia. This is the first UK study designed to examine the relationship of hypoglycaemia and ethnicity in a diverse ethnic population with Type 2 diabetes already prescribed intensive oral treatments and/or insulins using routine general practicerecorded primary care data, which included socio-economic status.
Materials and methods

Study design
An observational cohort study was performed using routinely collected primary care data from the electronic health records of patients from all 128 general practices in the east London CCGs of Tower Hamlets, Newham and Hackney (including the City of London) between 1 January 2013 and 31 December 2015. We securely extracted non-identifiable patient data from the electronic health records of patients registered with participating practices, using prespecified search terms (Appendix S1).
We included adults (aged >18 years) with Type 2 diabetes mellitus, prescribed either insulins or sulfonylureas in the 6 months prior to 1 January 2013, in the study population. The selection criteria are shown in Fig. 1 . The study population was divided into two cohorts: (1) people prescribed insulins with or without other antidiabetes medication, including sulfonylureas; and (2) those prescribed sulfonylureas with or without other antidiabetes drugs, excluding insulins.
The study cohorts were followed from 1 January 2013 to 31 December 2015. Individuals 'exited' the study early when they died or left the dataset. The date on which individuals left was defined as 6 months after the last prescription of insulins or sulfonylureas or a 'left' registration status recorded after the last prescription of either cohort medication. Individuals in the sulfonylurea cohort who commenced insulin after 1 January 2013 were switched to the insulin cohort on the date insulins were first prescribed. Similarly, those individuals prescribed both insulins and sulfonylureas who stopped receiving prescriptions for insulins were switched to the sulfonylurea cohort 6 months after the last prescription of insulins.
Hypoglycaemia was defined as any recording of one of several specified Read codes for hypoglycaemia (Appendix S1) or documented blood glucose measurements <3.9 mmol/l in the electronic health records. We limited the number of hypoglycaemia episodes to one per day if multiple were recorded. If multiple blood glucose measurements were recorded on the same day, only the lowest was included.
The main exposure was participants' self-reported ethnicity, categorized according to the 2001 UK national census, and recorded in the electronic health records using Read codes (Appendix S1). Nine categories of ethnicity were included in the analysis: white British; other White ethnicities; Indian; Pakistani; Bangladeshi; other South Asian; black Caribbean; black African and other black ethnicities. As a result of substantial heterogeneity, 'other' ethnicities and those whose ethnicity was not recorded were excluded from the final analysis.
Individual-level data on the following other potential confounders were also collected at baseline: age; sex; and socio-economic status (using Townsend Deprivation Index scores). Details of how these were handled in the multivariable models are given in Appendix S2.
Statistical analysis
We calculated crude incidence rates with 95% CIs of all recorded episodes of hypoglycaemia per 1000 person-years for each of the nine categories of ethnicity in each cohort. Using multivariable random effects Poisson regression, adjusting for clustering within CCGs, unadjusted and adjusted incidence rate ratios (IRRs) of hypoglycaemia by ethnicity with 95% CIs were calculated in each cohort. White British ethnicity was chosen as the reference category in the Poisson models. Missing data did not exceed 0.2% for any of the covariables measured (Table 1) ; therefore, people with missing data were excluded from the multivariable models.
What's new?
• This study explored ethnic group differences in the risk of hypoglycaemia among people with Type 2 diabetes prescribed insulins and/or sulfonylureas using primary care-recorded data, with near-complete ethnicity recording.
• Individuals of black Caribbean ethnicity prescribed either insulins and/or sulfonylureas, as well as black Africans and Indians prescribed sulfonylureas, were at increased hypoglycaemic risk compared with white British groups. Bangladeshi people prescribed insulins were at lower risk of hypoglycaemia than other South Asian groups.
• Such differences in hypoglycaemic risk warrant further investigation to determine the appropriateness of universal treatment targets across all ethnicities.
There were substantially more people with higher Townsend Deprivation Index scores, indicating greater deprivation, in the study area than the national average; therefore, quintiles of the study participants' scores rather than national quintiles were used in the multivariable analyses [14] .
The ethnicities of individuals who died or left the study group after stopping their medications were compared with the entire study population to assess for possible bias.
We used a likelihood ratio test to assess the fit of any interaction between cohort medications and the major We conducted a sensitivity analysis of the risks of hypoglycaemia associated with ethnic group for three levels of hypoglycaemia based on available blood glucose measurements: all hypoglycaemia, defined as any Read code for hypoglycaemia and/or blood glucose measurement <3.9 mmol/l; moderate to severe hypoglycaemia, defined as any Read code for hypoglycaemia and/or blood glucose measurement <3.5 mmol/l; and severe hypoglycaemia, defined as any Read code for hypoglycaemia and/or blood glucose <3.0 mmol/l (Appendix S3).
All analyses were undertaken using Stata 14 (StataCorp., College Station, TX, USA) [15] .
Ethics
This was a secondary analysis of non-identifiable routine primary care data, which was covered by an existing data sharing agreement between the research institution (Clinical Effectiveness Group, Queen Mary University of London) and each general practice providing routinely collected data. Ethics approval for this study was not required. Figure 1 shows the number of people included in the study. In the year of data extraction there were a total of 74 867 adults with Type 2 diabetes, of whom 19 771 were on insulin and/or sulfonylureas and were eligible for inclusion in the study; 7269 were assigned to the insulin cohort and 12 502 to the sulfonylurea cohort. Table 1 shows the baseline characteristics of the study population. Their mean (SD) age overall was 66.2 (13.3) years, and was 66.7 (13.3) years and 65.9 (13.3) years in the insulin and sulfonylurea cohorts, respectively. Men accounted for 53.5% of the overall cohort, and for 50.1% and 55.5% in the insulin and sulfonylurea cohorts, respectively.
Results
Most individuals were of South Asian ethnicity, 43.4% in the insulin cohort and 49.7% in the sulfonylurea cohort, with Bangladeshis comprising the largest majority in both cohorts, 23.8% and 27.3%, respectively. White Europeans accounted for 26.8% and 22.9% of the insulin and sulfonylurea cohorts, respectively, with most identifying as white British: 19.1% and 16.3% of each cohort, respectively. Individuals with black African/Caribbean ethnicities formed 25.1% and 22.2% of the insulin and sulfonylurea cohorts, respectively. Of these, black Caribbean people constituted 11.7% and 8.6%, respectively, and black African people 8.0% and 8.9%, respectively, of the insulin and sulfonylurea cohorts ( Table 1) .
The overall cohort contributed a total analysis time of 50 472 years, with an average of 2.55 years per individual. The incidence rates of hypoglycaemia were 50.6 events per 1000 person-years (95% CI 47.7, 53.8) in the insulin cohort and 25.5 per 1000 person-years (95% CI, 23.7,27.4) in the sulfonylurea cohort. Figure 2 shows the adjusted IRRs of hypoglycaemia in each cohort. After adjustment for all other covariables, black Caribbean people were at greater risk of hypoglycaemia than their white British counterparts [adjusted IRR 1.56 (95% CI 1.21, 2.01)], while Bangladeshi people had a lower risk [adjusted IRR 0.49 (95% CI 0.38, 0.64); Fig. 2 ]. No differences in hypoglycaemic risk were observed between other ethnicities and white British people in the insulin cohort. Tables showing the incidence rates, and unadjusted and adjusted Poisson regression models can be found in Appendix S3.
Insulin cohort
Sulfonylurea cohort
Among those prescribed sulfonylureas, both black Caribbean and black African people had higher risks of hypoglycaemia than white British people: adjusted IRR 1.63 There were no significant differences in the increased hypoglycaemic risk from insulin use among the other ethnic groups compared with the white British group (Appendix S3).
Of those commencing the study in the sulfonylurea cohort, 1427 from the nine ethnic groups included in the analysis switched to the insulin cohort on receiving a first prescription of insulin after the 1 January 2013. Similarly, 173 switched from the insulin to the sulfonylurea cohort (Appendix S3)
During the 3-year study period, 593 (8.2%) individuals in the insulin cohort died, and 572 (4.6%) died in the sulfonylurea cohort. In addition, 1454 people (20.0%) in the insulin cohort and 2991 (23.8%) in the sulfonylurea cohort left their registered general practice list or stopped receiving prescriptions of either cohort medication for ≥6 months prior to the end of the study period. Relative to the total number of people in both cohorts entering the study, a larger proportion of those who died were from the white British ethnic group (Appendix S3). There were no substantial differences in the ethnic distribution of those who left the study or stopped their medication for ≥6 months and those entering the study (Appendix S3).
Sensitivity analysis
Evidence of a greater relative risk of hypoglycaemia among those prescribed insulins identifying as black Caribbean compared with white British was found for all three models of hypoglycaemia: all hypoglycaemia; moderate to severe hypoglycaemia; and severe hypoglycaemia ( Table 2) . Table 2 Adjusted incidence rate ratios of all (blood glucose <3.9 mmol/l and Read code for hypoglycaemia), moderate-severe (blood glucose IRR, incidence rate ratio. Exponentiated coefficients; 95% CIs in brackets *P < 0.05, **P < 0.01, ***P < 0.001. †All hypoglycaemia: blood glucose <3.9 mmol/l and Read code for hypoglycaemia; moderate to severe hypoglycaemia: blood glucose <3.5 mmol/l and Read code for hypoglycaemia; severe hypoglycaemia: blood glucose <3.0 mmol/l and Read code for hypoglycaemia.
Furthermore, strong evidence of lower hypoglycaemic risk for Bangladeshi people prescribed insulins than for white British people was found in all three models. In the sulfonylurea cohort, Indian people were at significantly higher risk of hypoglycaemia in all three models. Black Caribbean and African people were at increased risk of hypoglycaemia in all three models, although this was only significant in the all hypoglycaemia and moderate to severe hypoglycaemia models (Table 2) .
Discussion
In the present study, we found that people of black Caribbean ethnicity with Type 2 diabetes prescribed insulins or sulfonylureas are at greater risk of hypoglycaemia than their white British counterparts, while Bangladeshi people had a lower risk. Among people prescribed sulfonylureas, those identifying as Indian, black Caribbean and black African were at greater risk of hypoglycaemia than white British people. Furthermore, Bangladeshi and Indian ethnicity diminished the increased relative hypoglycaemic risk associated with insulin use compared with sulfonylurea use in a combined cohort confounder-adjusted model. To our knowledge, this is the first study examining the differences in hypoglycaemia among ethnic groups with diabetes using general practice-recorded primary care data. Unlike previous studies, we evaluated a population with Type 2 diabetes only and examined the risks of hypoglycaemia in separate insulin and sulfonylurea cohorts.
The present study has several limitations. During the study period, 22.4% of the overall cohort did not have complete follow-up as a result of leaving the registered general practice list or stopping medication for ≥6 months; however, there were no major differences in the distribution of ethnicities among those who did not complete follow-up and those entering the study. Thus, although attrition of the cohort may have reduced the strength of associations observed in this study, it is unlikely to have influenced their direction. Of the 5.9% of the individuals who died, a larger proportion were of white British ethnicity compared to those entering the study. This may have led to bias in our findings if a substantial proportion of those who died experienced fatal hypoglycaemia. We did not have information on the cause of death and were thus unable to explore this further. In both cohorts, however, people of white European ethnicity were generally older than other ethnic groups except the black Caribbean group (Appendix S3). Older age, which may partially account for the higher mortality among white British individuals, was adjusted for in the multivariable Poisson models estimating hypoglycaemic risk.
The present study is subject to the limitations of routinely collected clinical data, whereby inaccuracies and inconsistencies in the recording of both outcomes and exposures can lead to bias in the findings. We were unable to account for clustering of participants within general practices, among which diabetes management, including attention to hypoglycaemia, and ethnic group demographics may differ; however, we did cluster participants by the CCG area within which they were registered with their general practice. This is likely to account for some inter-practice variation attributable to shared funding priorities, prescribing practices, infrastructure, secondary care support and demographics of general practices within each CCG.
We did not have direct access to hospital records and were therefore unable to capture directly all hypoglycaemic episodes recorded in hospital settings, only some of which may have been recorded in the general practice record. Given that only 4.7% of hypoglycaemia is estimated to be reported to a clinician, previous studies looking at hospital episodes are likely to have captured only the severest cases [16, 17] . By contrast, this study used a broader definition of hypoglycaemia to capture a range of severities. Although most Read codes used by primary care clinicians do not indicate the severity of hypoglycaemia experienced, it is likely that they refer to symptomatic hypoglycaemia resulting in the assistance of a clinician being sought and hypoglycaemia being recorded. In addition, we also included any documented blood glucose <3.9 mmol/l; therefore, our definition of hypoglycaemia accords with the classifications of clinically important and serious hypoglycaemia for use in clinical studies as defined by the American Diabetes Association Workgroup on Hypoglycaemia [18] . To avoid including multiple recordings of a single hypoglycaemic episode, we excluded any additional episodes recorded on the same day.
We did not collect information on dosage or on individuals' level of medication adherence so were unable to account for this in the analysis.
Our results reflect those of Zaccardi et al. [4] who found increased hypoglycaemic risk among black Caribbean compared with white British individuals with either Type 1 or Type 2 diabetes hospitalized in the UK with hypoglycaemia. They found the risk of hypoglycaemia to be lower among Bangladeshi, Indian and Pakistani people [4] ; however, we have shown that ethnic differences in hypoglycaemic risk vary according to the type of intensive diabetic treatment used, with lower risk among Bangladeshi people prescribed insulins, while Indian and black African people prescribed sulfonylureas also had greater hypoglycaemic risk. However, when investigating the impact of ethnicity, the Hospital Episode Statistics database from which Zaccardi et al. drew their data may be less reliable than primary care datasets because up to a half of ethnicity codes recorded at hospital admission have been reported as 'unknown' or missing [19] .
Our findings are also consistent with studies of people with diabetes in North America, which have found AfricanAmerican people to be at higher risk of hypoglycaemia than white European people [6, 7, 20, 21] . Karter et al. [8] performed a 7-year longitudinal study in people with Type 1 or ª 2018 Diabetes UK Type 2 diabetes prescribed insulin and/or sulfonylureas and found that African American people had consistently higher rates of severe hypoglycaemia than white Europeans, while Latino and Asian people had lower rates.
The higher risk of hypoglycaemia found among black African/Caribbean ethnic groups may be partly explained by relatively intensive glycaemia targets in these ethnic groups. Black African/Caribbean and South Asian ethnic groups tend to have higher HbA 1c levels at a given blood glucose than their white European counterparts [22, 23] . Consequently, these individuals may be at greater risk of hypoglycaemia than white European populations when lowering HbA 1c to national and international glycaemic targets.
The observed variation in hypoglycaemic risk between the insulin and sulfonylurea cohorts, particularly among the Bangladeshi, Indian and black African groups suggests possible differences in biological and/or cultural responses to insulins and sulfonylureas. For instance, South Asian people are known to be less likely to accept insulin and, if prescribed, are more likely to use basal insulins, associated with less dramatic falls in blood glucose when administered [11, 12, 24] . This may provide some explanation for the significant modifying effect of Bangladeshi and Indian ethnicity on the observed hypoglycaemic risk associated with insulin use.
Furthermore, genetic factors influencing the effectiveness of sulfonylureas in different ethnicities, such as poor therapeutic responses among white European people, may also have contributed to the higher relative risk of hypoglycaemia observed among the black Caribbean, black African and Indian ethnic groups in the sulfonylurea cohort [25] .
In conclusion, the present study adds to the evidence of variation in propensity to hypoglycaemia by ethnic group. It identified greater hypoglycaemic risk among black populations with Type 2 diabetes in primary care who were using either insulins or sulfonylureas, as well as higher risks in South Asian vs white British ethnic groups on sulfonylureas. Further investigation of ethnic differences in hypoglycaemia using larger nationally representative primary care datasets is recommended to inform policy on appropriate treatment targets by ethnic group.
